Selective EP4 receptor antagonistic substance for treatment of cancer
This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.
1. A method for treatment of an epithelial cancer expressing PGE2, which comprises administering an effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof to a human or an animal in need thereof.
2. The method according to claim 1 , wherein the epithelial cancer expressing PGE2 is selected from the group consisting of basal cell carcinoma, adenocarcinoma, gastroenterological cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, prostate cancer, and renal cell carcinoma.
3. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is ovarian cancer.
4. The method according to claim 1 , wherein the 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof is administered to the human or animal orally.
5. The method according to claim 1 , wherein the method further comprises shrinking epithelial cancer tissues.
6. The method according to claim 2 , wherein the epithelial cancer tissues are ovarian cancer tissues expressing PGE2 is gastroenterological cancer.
7. The method according to claim 6 , wherein the gastroenterological cancer is selected from the group consisting of lip cancer, oral cancer, esophageal cancer, intestinal cancer, colon cancer, colorectal cancer, and gastric cancer.
8. The method according to claim 7 , wherein the gastroenterological cancer is lip cancer.
9. The method according to claim 7 , wherein the gastroenterological cancer is oral cancer.
10. The method according to claim 7 , wherein the gastroenterological cancer is intestinal cancer.
11. The method according to claim 7 , wherein the gastroenterological cancer is esophageal cancer.
12. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is liver cancer.
13. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is cervical cancer.
14. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is skin cancer.
15. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is pancreatic cancer.
16. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is renal cell carcinoma.
17. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is bladder cancer.
18. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is basal cell carcinoma.
19. The method according to claim 2 , wherein the epithelial cancer expressing PGE2 is adenocarcinoma.
20. A method for reducing epithelial cancer cells expressing PGE2 comprising contacting the epithelial cancer cells expressing PGE2 with 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof.